NCT07267260RecruitingPhase 2
Evaluating the Efficacy of Vonoprazan in Preventing Post-Endoscopic Variceal Band Ligation Ulcers: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 26 Dec 2025
Brief summary (registry, in English)
The goal of this clinical trial is to learn if the medicine vonoprazan can help prevent ulcers that may develop after endoscopic variceal band ligation (EVBL) in adults with liver cirrhosis. These ulcers sometimes cause pain or delayed bleeding after the procedure. The study will also look at how well vonoprazan is tolerated and if it improves comfort after the procedure. The main questions this study will answer are: Does vonoprazan lower the number and severity of ulcers found on endoscopy after EVBL? Does vonoprazan reduce swallowing pain or chest discomfort compared with placebo? Is vonoprazan safe and well tolerated in people with liver cirrhosis? Researchers will compare vonoprazan 20 mg once daily with a placebo (a look-alike tablet that contains no active medicine) to see if vonoprazan works better to prevent these ulcers. Participants will: Take vonoprazan or placebo by mouth once daily for 14 days after EVBL. Return for a follow-up endoscopy about two weeks later to check for ulcers. Report any symptoms such as pain, nausea, or swallowing difficulty during the study. Adults aged 18 to 75 years with liver cirrhosis who undergo EVBL will be invited to join. Participants will be randomly assigned to one of two groups, and neither they nor the study doctors will know which treatment they receive (double-blind design). The study will take place at Mayo Hospital, Lahore, Pakistan, over about six months. By comparing vonoprazan to placebo, researchers hope to find a better way to protect the esophagus and stomach after EVBL, reduce post-procedure pain, and support faster recovery in people with liver cirrhosis.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 154 (estimated)
- First submitted
- 23 Nov 2025
- Start date
- 16 Dec 2025
- Primary completion date
- 30 Jan 2026
- Lead sponsor
- King Edward Medical University
- Diseases
- High blood pressure
- NCT number
- NCT07267260
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 154
- From 16 Dec 2025 to the primary completion date, 30 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of gastric or esophageal surgery
- Allergy or contraindication to vonoprazan or study drug components
- Active gastrointestinal bleeding at the time of enrollment
- Malignancy of the upper gastrointestinal tract
Other
- Pregnant or lactating women
- Individuals who are non-cooperative or unable to understand local languages
- Critically ill patients, including:
- ICU admission Requirement for mechanical ventilation GCS \< 10
Who the study is looking for
- Adults aged 18 to 75 years (male or female)
- Diagnosis of liver cirrhosis confirmed by clinical, biochemical, or imaging findings.
- Presence of documented esophageal varices requiring endoscopic variceal band ligation (EVBL).
- Able and willing to provide written informed consent in English or Urdu.
- Willing to comply with study procedures, including taking study medication and attending follow-up endoscopy.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| King Edward Medical University/Mayo Hospital Coordinator of this site? Confirm its status | Lahore | Pakistan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.